0031 RCE

				reons are required to res	Approved for use through 10/31/99 OMB 065 Patent as demark Office; U.S. DEPARTMENT OF COMM spond to a collection of information unless it displays a valid OMB control number					
•					Complete if Known					
		21.			Application Number	10/020,733				
-7	INF	ORMATION D)IS(CLOSURE	Filing Date	10/30/01				
<u>``</u>		er the Paperwark Reduction Act of 1995, no persons are required to substitute or form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Walke					
`	(S)	AIEMENI DI	МГ	FLICAIT	Group Art Unit	1645 / 6.52				
<i>,</i>	ի,	tuse as many sheets.	as neci	essano.	Patent at Indemark Office; U.S. DEPARTMENT is are required to respond to a collection of information unless it dispers a valid OMB control number Complete if Known Application Number 10/020,733 Filing Date 10/30/01 First Named Inventor Walke Group Art Unit 1645 / 6.52 Examiner Name To be assigned Moore	To be assigned Moore				
\mathcal{O}			-4	,	Attarney Deaket Number	LEX-0263-USA				

			U.S. PATENT DOCUMENT	rs	
Examiner Hials*	Cite No.¹	U S. Patent Document Kind Code ² Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
(ast) a seta	AA	4,215,051	Schroeder et al	07/29/80	
37	AB	4,376,110	David et al	03/08/83	
\$/	AC	4,594,595	Struckman	06/10/86	
7	AD	4,631,211	Houghten	12/23/86	
	AE	4,689,405	Frank et al	08/25/87	
	AF	4,713,326	Dattagupta et al	12/15/87	
	AG	4,873,191	Wagner et al	10/10/89	
	AH	4,946,778	Ladner et al	08/07/90	
	Al	5,252,743	Barrett et al	10/12/93	
	AJ.	5,272,057	Smulson et al.	12/21/93	
	AK	5,424,186	Fodor et al	06/13/95	
	AL	5,445.934	Fodor et al	08/29/95	
\neg	AM	5,459,127	Felgner et al	10/17/95	
	AN	5,556,752	Lockhart et al	09/17/96	
	AO	5,700,637	Southern	12/23/97	
	AP	5,744,305	Fodor et al	04/28/98	
	AQ	5,830,721	Stemmer et al	11/03/98	
	AR	5,837,458	Minshull et al	11/17/98	
1	AS	5,869,336	Meyer et al.	02/09/99	
1	AT	5,877,397	Lonberg et al	03/02/99	
	AU	5,948,767	Scheule et al.	09/07/99	
	AV	6,075,181	Kucherlapati et al	06/13/00	
W	AW	6,110,490	Thierry	08/29/00	
wwn	AX	6,150,584	Kucherlapati et al.	11/21/00	

Examiner Signature	William Neva	Date Considered	10 October 2003
			to the state of the semileness and

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no perons are required to respond to a collection of information unless it displays a valid OMB control number.

Subs	stitute for form 1449B/P	то		Complete if Known		
INIE	ORMATION	ו חופרו	OSLIDE	Application Number	10/020,733	
				Filing Date	10/30/01	
SIA	ATEMENT	RA YAA	LICANI	First Named Inventor	Walke	
				Group Art Unit	1645 /652	
	(use as many st	neets as necessa	ury)	Examiner Name	In be assigned Moore	
Sheet	2	of	3	Attorney Docket Number	LEX-0263-USA	

			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exa	miner als*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
las	MUN	γAY	Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.	
12.	آ ک	ΑZ	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.	Ĺ
	A. A.	ва	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.	
	, , , , , , , , , , , , , , , , , , ,	BB	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research 15(16):6625-6641.	
		вс	Gordon, 1989, "Transgenic Animals", International Review of Cytology, 115:171-229.	
		BD	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444.	
		BE	Gu et al, 1994, "Deletion of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting", Science 265:103-106.	
		BF	Huse et al, 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science 246:1275-1281.	
			Huston et al, 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single- chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883.	
			Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS Letters 215(2):327-330.	
			Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides", Nucleic Acids Research 15(15):6131-6149.	
			Inouye & Inouye, 1985, "Up-promoter mutations in the lpp gene of Escherichia coli", Nucleic Acids Research 13(9):3101-3110.	
			Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PNAS 88:8972-8976.	
			Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.	
			Lakso et al, 1992, "Targeted oncogene activation by site-specific recombination in transgenic mice", Proc. Natl. Acad. Sci. USA 89:6232-6236.	
			Lavitrano et al, 1989, "Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice", Cell 57:717-723.	
			Lo, 1983, "Transformation by Iontophoretic Microinjection of DNA Multiple Integrations without Tandem Insertions", Mol. Cell. Biology 3(10):1803-1814.	te of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the agazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. T ² e-Chain Antigen-Binding Proteins", Science 242 423-426. ression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544. 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1DNA IV:α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating e. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research penic Animals", International Review of Cytology. 115:171-229. "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444. on of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting", eration of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", 1. total engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-duced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883. uence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS of thesis and hybridization studies on two complementary nona(2"-O-methyl)ribonucleotides", Nucleic :6131-6149. "Up-promoter mutations in the lpp gene of Escherichia coli", Nucleic Acids Research 13(9):3101- "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant 38:8972-8976. "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature geted oncogene activation by site-specific recombination in transgenic mice", Proc. Natl. Acad. 3. Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice", ion by Iontophoretic Microinjection of DNA Multiple Integrations without Tandem Insertions", Mol. 3. 3-1814.
	V		Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.	
WIA	77/1	BQ	Lowy et al, 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817-823.	

Examiner	1.511 . 11	Date	011
Signature	William W.W.	Considered	100ctobar 2003

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Emark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Subs	stitute for form 1449B/PTO			Complete if Known			
INE	ORMATION D	אוכו	CLOSURE	Application Number	10/020,733		
				Filing Date	10/30/01		
214	ATEMENT BY	AF	PLICANT	First Named Inventor	Walke		
				Group Art Unit	1645 1652		
	(use as many sheets	as nec	essary)	Examiner Name	To be assigned Moore		
Sheet	3	of	3	Attorney Docket Number	LEX-0263-USA		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	-
www	BR	Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA 81:6851-6855.	
4	BS	Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.	
re r	вт	Neuberger et al, 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.	
	BU	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of Immunology 147:2429-2438.	
	BV	O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.	
	BW	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.	
	ВХ	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.	
	BY	Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.	
	ВZ	Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.	
	CA	Stein et al. 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.	
	СВ	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.	
	CC	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.	
	CD	Thompson et al, 1989, "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targetin in Embryonic Stem Cells", Cell 56:313-321.	9
	CE	Van Der Putten et al, 1985, "Efficient insertion of genes into the mouse germ line via retroviral vectors", Proc. Natl. Acad. Sci. USA 82:6148-6152.	
	CF	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemistry 264(10):5503-5509.	
	CG	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature 341:544-546.	
V	СН	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223-232.	
wwn	СІ	Wigler et al, 1980, "Transformation of mammalian cells with an amplifiable dominant-acting gene", Proc. Natl. Acad. Sci. USA 77(6):3567-3570.	

Signature MMMen W. More Considered W October 2003	Examiner Signature	Millen W. Moore	
---------------------------------------------------	-----------------------	-----------------	--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)

		us sign (+) inside this box		re required to rest	Patent and T Paten				
	ν `	te fortom 1449A/PTO			}	Complete if Known			
1	APR 2 1 20	m & 200	_		Application Number	10/020,733			
1		SUPPLEM	EN.	TAL	Filing Date	10/30/01			
P.	INFO	PANATION D	120	LOSHRE	First Named Inventor	Walke			
/	1 miner	EMENT BY	45	LUCUIT	Group Art Unit	165 ASA			
	STAT	FWENI BA	API	PLICANI	Examiner Name	To be assigned Morry			
	Sheet	1	of	2	Attorney Docket Number	LEX-0263-USA			

				U.S. PATENT DOCUMEN	TS	
Examiner Initials*	Cite No.¹	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
						Figures Appear
		<u> </u>				
						T \ 1
						<u></u>
						5 20 4
						7.5
						<u> </u>
j						0
			- - - - - - - - - - 			
			 -	-	 	
						

				FORE	IGN PATENT DOCUMENTS			
Examiner	Cite	Foreign Patent Document			Name of Patentee or Applicant	Date of	Pages, Columns, Lines,	T
initials*	No.¹		Number ⁴	Kind Code ^s (<i>if known</i>)	of Cited Document	Publication of cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Ţ
www	CJ	wo	97/09420	A2	Celltech Therapeutics Ltd.	03/13/97		Т
www	СК	wo	00/73323	A2	Human Genome Sciences Inc	12/07/00		
								丄

Examiner Signature	Willen W. More	Date Considered	10 October 2003
			10001000

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	10	a plus sign (+) inside this		rsons are required to	respond to a collection of information	PTO/SB/08B (10-9 Approved for use through 10/31/99, OMB 0651-00: Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC unless it displays a valid OMB control number.	3í
Substitute for form 1449B/PTO					Complete if Known		
		SUPPLE!	MENT	ΔΙ	Application Numb r	10/020,733	
13.	INITA	ATION!			Filing Dat	10/30/01	
100	IINFC	JEWIA HON	DISCL	OSURE	First Named Inventor	Walke	
- 19	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Group Art Unit	164F 1652			
- 1		<u>,</u>			Examiner Name	Tobe assigned Murre	
ŀ	Sheet	,	of	2	Attornoy Dooket Number	LEV 0363 LICA	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
irum	CL	Fritsche, J. et al., "Molecular cloning and characterization of a human metalloprotease disintegrin - a noval marker for dendritic cell differentiation," 07/15/00, Blood, Vol. 96, No. 2, pgs. 732-739, XP001119962.			
/www	СМ	Database EMBL 'Online', ADAM gene 2, 03/20/01, RUBEN et al., retrieved from EMBL, Database accession no. AAC91177, XP002236360, abstract.			
CN WEI, P. et al., "Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta 01/26/01, Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, FL, Vol. 280, No. pgs. 744-755, XP001120634, ISSN: 0006-291X.					
		International Search Report, International Application No. PCT/US01/48498_10/39/91-(Attorney Decket No. EEX-0203-PCT)			
			_		
		<u> </u>	-		
		2003 2003 2003 2000			
		5			
	}				
	[
			\dashv		

Examiner Signature	1111/h. 11 Maria	Date Considered	10 Others
- 3	11 WILL 1 1 1 WO K	1 Och Sidered	1 W / Jerobu 1005

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.